Exocrine Pancreatic Insufficiency (EPI) Treatment Market Growth Driven by Pancreatic Enzyme Replacement Therapy (70%)Trends in Cystic Fibrosis, Chronic Pancreatitis & Nutritional Support Solutions Key Players: AbbVie, Sanofi, and Takeda Leading Innovation

The Exocrine Pancreatic Insufficiency (EPI) Treatment Market reached US$ 1.72 billion in 2023 and is expected to reach US$ 3.18 billion by 2031, growing at a CAGR of 8.3% from 2024 to 2031, driven by the rising prevalence of conditions leading to EPI including chronic pancreatitis, cystic fibrosis, and pancreatic cancer as well as increased awareness and diagnosis of digestive disorders. Effective management of EPI is critical to improving nutrient absorption and patient quality of life, which is boosting the demand for advanced treatment options.

Growth is supported by the expanding use of pancreatic enzyme replacement therapies (PERTs), which help restore digestive function by supplying critical enzymes such as lipase, amylase, and protease. These therapies play an essential role in alleviating symptoms such as malnutrition, steatorrhea, and weight loss. Additionally, increased focus on early diagnosis and screening, improvements in formulation technologies, and the development of novel enzyme delivery systems are enhancing patient compliance and treatment outcomes. Rising healthcare expenditure, expanding geriatric population, and growing recognition of EPI in clinical practice further accelerate market growth. Continuous innovation in drug formulations, combined with strong clinical evidence supporting treatment efficacy, continues to propel the global exocrine pancreatic insufficiency treatment market forward.

Download your exclusive sample report today (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/exocrine-pancreatic-insufficiency-treatment-market?sindhuri

Exocrine Pancreatic Insufficiency (EPI) Treatment Market: Competitive Intelligence
The Exocrine Pancreatic Insufficiency Treatment Market is strongly driven by major global pharmaceutical, biotechnology, and specialty therapeutic companies such as AbbVie Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Nestlé Health Science (via its Althéra and Peptamen portfolios), Viatris Inc., Fresenius Kabi AG, Cipla Limited, Abbott Laboratories, Aeterna Zentaris Inc., and Digestive Care Inc., among others. These companies develop and commercialize enzyme replacement therapies, nutraceutical supplements, and supportive nutritional formulations used to manage exocrine pancreatic insufficiency (EPI), a condition characterized by insufficient pancreatic enzyme production leading to maldigestion and nutrient deficiencies.

Market growth is primarily fueled by the rising global prevalence of chronic pancreatitis, cystic fibrosis, pancreatic cancer, and other gastrointestinal disorders that impair pancreatic function. The growing elderly population and increasing incidence of metabolic and digestive diseases are further driving demand for effective EPI treatments that improve nutrient absorption, alleviate gastrointestinal symptoms, and enhance patients' quality of life.

Pharmaceutical companies are increasingly focusing on innovative pancreatic enzyme replacement therapies (PERT), optimized formulation delivery systems, and tailored nutritional support products that enhance treatment efficacy and patient compliance. Clinicians are also adopting multidisciplinary approaches that combine pharmacologic enzyme therapy with dietary modifications and specialized nutrition to achieve better clinical outcomes for EPI patients.

These companies' complementary strengths include AbbVie's strong portfolio of pancreatic enzyme therapies and global distribution capabilities; Sanofi's expertise in digestive health products; Takeda's research investments in gastrointestinal disorders; and Nestlé Health Science's extensive range of clinical nutrition and enzyme supplement solutions. Additional players such as Viatris, Fresenius Kabi, Cipla, Abbott Laboratories, Aeterna Zentaris, and Digestive Care further strengthen the competitive landscape through specialized formulations, regional market presence, and strategic collaborations with healthcare providers focused on EPI management.

Strategic focus areas across the industry include the development of improved enzyme formulations with enhanced bioavailability, sustained‐release delivery systems, personalized nutritional therapy programs, and patient education initiatives to support long‐term disease management. Companies are also investing in clinical research, real‐world evidence studies, and partnerships with gastroenterology specialists to expand treatment options, refine dosing protocols, and address unmet needs in EPI care.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/exocrine-pancreatic-insufficiency-treatment-market?sindhuri

Recent Key Developments - United States & North America
✅ June 2025: AbbVie Inc. expanded its portfolio of pancreatic enzyme replacement therapies (PERTs) to improve treatment outcomes for patients with exocrine pancreatic insufficiency (EPI).
✅ May 2025: Nestlé Health Science strengthened its digestive health product line with specialized enzyme formulations and nutritional supplements targeting EPI patients.
✅ 2025: Rising prevalence of cystic fibrosis, chronic pancreatitis, and post-surgical pancreatic conditions, along with growing awareness of digestive disorders, drove adoption of EPI treatments across North America.

Recent Key Developments - Japan & Asia-Pacific
✅ July 2025: Kissei Pharmaceutical Co., Ltd. expanded clinical trials and distribution of PERT formulations in Japan to improve therapeutic access for EPI patients.
✅ Early 2026: GSK plc introduced innovative enzyme therapies and patient support programs across China, India, and Southeast Asia.
✅ 2025: Growing diagnosis rates of pancreatic disorders, expanding healthcare infrastructure, and increasing awareness among clinicians and patients boosted demand for EPI treatments in Asia-Pacific.

Recent Key Developments - Product & Technology Innovation
✅ 2025: Advanced Pancreatic Enzyme Formulations: Development of enteric-coated, delayed-release enzyme capsules improved nutrient absorption and reduced gastrointestinal side effects.
✅ Combination Therapies & Nutritional Support: Integration of enzyme replacement with tailored nutritional supplements enhanced patient adherence and overall digestive health outcomes.
✅ Digital Health & Patient Monitoring: Mobile apps and smart adherence tools enabled real-time monitoring of enzyme intake, symptom tracking, and personalized therapy adjustments for improved disease management.

Mergers, Acquisitions & Strategic Partnerships
✅ 2025 - Abbott Laboratories Expansion in Digestive Health
Abbott Laboratories expanded its exocrine pancreatic insufficiency (EPI) treatment portfolio through strategic acquisitions and collaborations with specialty pharma companies.
The initiative strengthens Abbott's capabilities in pancreatic enzyme replacement therapies (PERT) and nutritional support products for patients with EPI.
✅ 2024 - Nestlé Health Science Partnership with Clinical Research Centers Nestlé Health Science partnered with hospitals and research institutions to advance clinical programs for EPI treatment solutions.
The collaboration focuses on improving enzyme formulations, patient adherence, and nutritional outcomes in both pediatric and adult populations.

New Product Launches & Therapeutic Innovations
✅ 2025 - Advanced Pancreatic Enzyme Replacement Therapies (PERT)
Pharmaceutical companies introduced next-generation PERT formulations with improved enzyme stability, targeted delivery, and reduced dosing frequency.
These therapies help patients with EPI digest nutrients more efficiently and maintain optimal nutritional status.
✅ 2024 - Combination Therapies with Nutritional Support
Manufacturers launched enzyme-nutrient combination products that provide both digestive enzymes and essential vitamins/minerals.
These innovations address malabsorption issues while simplifying patient regimens for improved adherence and quality of life.

R&D and Scientific Development
✅ Development of Improved Oral Enzyme Formulations
Researchers are developing enteric-coated and pH-stable enzyme capsules to enhance bioavailability and effectiveness in EPI treatment.
These advancements reduce gastrointestinal side effects and ensure enzymes remain active in the small intestine.
✅ Exploration of Adjunctive Therapies and Personalized Treatments
R&D initiatives focus on combining PERT with probiotics, prebiotics, or novel digestive aids for tailored patient care.
These approaches aim to optimize digestion, support gut health, and improve clinical outcomes in individuals with exocrine pancreatic insufficiency.

Purchase Corporate License | Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=exocrine-pancreatic-insufficiency-treatment-market?sindhuri

Segments Covered in the Exocrine Pancreatic Insufficiency (EPI) Treatment Market:
By Treatment
The market is segmented into pancreatic enzyme replacement therapy (PERT) (70%), acid-suppressing agents (15%), and nutritional support therapy (15%).Pancreatic enzyme replacement therapy dominates due to its established efficacy in replacing deficient digestive enzymes and improving nutrient absorption. Acid-suppressing agents are used to enhance enzyme activity, while nutritional support therapy is gaining traction to manage malnutrition and associated complications in EPI patients.

By Application
Applications include cystic fibrosis (40%), chronic pancreatitis (30%), pancreatic cancer (15%), and other gastrointestinal disorders (15%).Cystic fibrosis dominates due to the high prevalence of EPI in these patients. Chronic pancreatitis is also a major driver, as patients often require long-term enzyme replacement. Pancreatic cancer and other GI disorders contribute to steady demand, particularly in regions with increasing incidence of pancreatic diseases.

By Distribution Channel
Distribution channels comprise hospital pharmacies (40%), retail pharmacies (35%), and online pharmacies (25%).Hospital pharmacies dominate due to direct prescriptions and management of EPI patients in clinical settings. Retail pharmacies support widespread availability, while online pharmacies are witnessing growth due to convenience and increasing adoption of e-pharmacy platforms.

By Region
North America - 40% Share
North America leads the market due to high prevalence of cystic fibrosis, strong healthcare infrastructure, and wide adoption of pancreatic enzyme replacement therapies in the U.S. and Canada.

Europe - 30% Share
Europe holds a significant share driven by the presence of advanced healthcare systems, awareness programs, and increasing diagnosis of chronic pancreatitis and cystic fibrosis in Germany, France, and the U.K.

Asia-Pacific - 20% Share
Asia-Pacific is witnessing growth due to rising awareness of EPI, expanding healthcare infrastructure, and increasing availability of treatments in China, India, Japan, and South Korea.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoringa
✅ Live Market & Pricing Trend

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.